Couples with fertility issues are unable to conceive even after regular unprotected coitus (six months if the woman is over age 35). Female or male infertility factors account for one-third of the cases, where a couple is unable to conceive. In the rest of the cases, the cause is either unknown or a combination of both male and female infertility factors.
In males, low sperm production, abnormal sperm function, or blockages that prevent the delivery of sperm can lead to infertility. In females, hormonal changes, fallopian tube damage, endometriosis, and cervical abnormalities can lead to infertility. Diagnosing the cause of infertility can be difficult but people with fertility issues have many treatment options depending on the underlying problem.
Technavio’s analysts forecast the fertility services market in the US to grow at a CAGR of 4.07% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the fertility treatment market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of fertility drugs and the use of assisted reproductive technology (ART).
The market is divided into the following segments based on treatment type:
Technavio Announces the Publication of its Research Report – Fertility Market in the US 2016-2020
Technavio recognizes the following companies as the key players in the Fertility Market in the US: Cellcura, CooperSurgical, Intramed, Ferring Pharmaceuticals and Merck
Other Prominent Vendors in the market are: Abbott Laboratories, AbbVie, Actavis, Apricus Biosciences, AstraZeneca, Auxogyn, Bristol-Myers Squibb, Elelixis Diagnostics, Eli Lilly, EMD Serono, IKS International, In Vitro Care, Invo Bioscience, Irvine Scientific, IVFtech Aps, Life Global, Medical Electronic Systems, Meditex, Novartis, Ovascience, Pantec Biosolutions, Pfizer, Sanofi, Vivus, and Xytex Cryo International.
Commenting on the report, an analyst from Technavio’s team said: “Vendors undergo M&A to expand their geographical presence, enhance their product portfolio, and attain profit margins. M&A allows vendors to gain proprietary technologies and innovative products of the acquired company. Small vendors undergo M&A to broaden their network and expand people's access to their new products.”
According to the report, the fertility market in the US consists of fertility drugs and assisted reproductive technology (ART) services segments. Increasing fertility issues among the aging population, rising disposable income, growing adoption of fertility services by homosexual couples, and augmented support from the US federal government are some of the major factors that will impel growth in this market during the forecast period.
Further, the report states that high cost of fertility treatment hinders the market growth.
Cellcura, CooperSurgical, Intramed, Ferring Pharmaceuticals, Merck, Abbott Laboratories, AbbVie, Actavis, Apricus Biosciences, AstraZeneca, Auxogyn, Bristol-Myers Squibb, Elelixis Diagnostics, Eli Lilly, EMD Serono, IKS International, In Vitro Care, Invo Bioscience, Irvine Scientific, IVFtech Aps, Life Global, Medical Electronic Systems, Meditex, Novartis, Ovascience, Pantec Biosolutions, Pfizer, Sanofi, Vivus, Xytex Cryo International.